Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2018-07-06 Capital/Financing Update
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2018
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 29, 2018, for Propanc Biopharma, Inc. The content details the entry into a material definitive agreement involving convertible promissory notes and related financing terms. It describes the terms of the securities purchase agreement, notes, covenants, events of default, and collateral arrangements. This is a current report disclosing a capital raising transaction and financing update rather than a full financial report or earnings release. There is no indication of financial statements or earnings data, nor is it a regulatory certification or announcement of a report publication. The primary focus is on financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-07-06 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the issuance of a convertible promissory note, detailing terms of the note, conversion rights, default penalties, and use of proceeds. This is a clear update on a financing activity involving capital raising through convertible debt. The document is not a full financial report but an announcement of a material definitive agreement related to financing. Therefore, it fits best under Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2018-07-02 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a convertible promissory note, detailing terms of the note, conversion rights, default penalties, and related financial obligations. There are no financial statements or comprehensive financial performance data presented, only disclosure of a financing transaction. This fits the category of Capital/Financing Update (CAP), as it updates on company fundraising and capital structure changes. The document length is sufficient and contains detailed terms of the financing agreement, confirming it is not a brief announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2018-06-20 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Q3 2018
2018-05-10 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 13, 2018, by Propanc Biopharma, Inc. It details the entry into a material definitive agreement involving convertible promissory notes and related financing terms with GS Capital Partners, LLC. The content focuses on the terms of the securities purchase agreement, convertible notes, interest rates, conversion rights, events of default, and collateral arrangements. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other types of filings. Instead, it is a current report disclosing a significant financing transaction and related obligations. This fits the definition of a Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2018-04-19 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a 'Current Report' pursuant to the Securities Exchange Act of 1934, dated April 10, 2018. The content describes the announcement of a scientific advice meeting completion with a regulatory agency and includes a press release as an exhibit. There are no financial statements or detailed financial data present, and the document is relatively short (3473 characters). It is primarily an announcement of an event rather than a full financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2018-04-10 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.